HIGHLIGHTS
- who: Ziyi Wang from the Affiliated Hospital of China Medical University, Shenyang, China have published the research work: The Emerging Roles of Rad51 in Cancer and Its Potential as a Therapeutic Target, in the Journal: (JOURNAL)
- what: Rad51 has been observed to be dysregulated in various tumor types, and associated with unfavorable clinicopathological factors and prognosis.
SUMMARY
The authors initially introduced the structure, expression pattern of Rad51 and key Rad51 mediators involved in July 2022 | Volume 12 | Article 935593 Rad51 in Cancer mobility group A1 (HMGA1) can directly bind to A . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.